ImmunityBio, Inc. (NK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1241474,
    "name": "ImmunityBio, Inc.",
    "stock_name": "ImmunityBio, Inc.",
    "full_name": "ImmunityBio, Inc.",
    "name_url": "stocks-analysis/immunitybio-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.30",
    "chg": 0.21,
    "chgp": "10.05%",
    "dir": 1,
    "prev_price": "2.09",
    "mcapval": "2,278.46",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US45256X1037",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "24.05 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/immunitybio-inc-1241474-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ImmunityBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/immunitybio-inc-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-price-increase-3652109",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ImmunityBioInc_technicaldot_3652109.png",
        "date": "2025-10-28 15:49:53",
        "description": "ImmunityBio, Inc. has recently revised its evaluation amid market fluctuations, with its stock price at $2.66. The company has experienced significant volatility over the past year, with a 52-week high of $6.82 and a low of $1.83. Its performance has lagged behind the S&P 500 in both short and long-term comparisons."
      },
      {
        "title": "Is ImmunityBio, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immunitybio-inc-technically-bullish-or-bearish-3651509",
        "imagepath": "",
        "date": "2025-10-28 11:44:58",
        "description": "As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on the weekly timeframe but bearish on the monthly, while the RSI is bullish weekly but shows no signal monthly. Bollinger Bands and KST indicate a bearish outlook on both weekly and monthly periods. Moving averages are bearish on the daily timeframe, and Dow Theory reflects a mildly bearish stance weekly with no trend monthly. \n\nIn terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -41.33% compared to the S&P 500's 16.90%, and a 5-year return of -71.21% versus 95.99% for the index...."
      },
      {
        "title": "Is ImmunityBio, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immunitybio-inc-technically-bullish-or-bearish-3647962",
        "imagepath": "",
        "date": "2025-10-27 11:56:00",
        "description": "As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis, while the RSI indicates bullish momentum weekly but shows no signal monthly. Bollinger Bands and KST are both mildly bearish on a weekly basis, and moving averages are bearish daily. The Dow Theory reflects a mildly bearish stance weekly with no trend monthly. Overall, the mixed signals suggest caution, and there is no available return data to compare the company's performance against the S&P 500...."
      },
      {
        "title": "Is ImmunityBio, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immunitybio-inc-technically-bullish-or-bearish-3646494",
        "imagepath": "",
        "date": "2025-10-26 11:31:07",
        "description": "As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators: the MACD is mildly bullish on a weekly basis but bearish monthly, while the RSI is bullish weekly with no signal monthly. However, moving averages are bearish daily, and the KST and Dow Theory indicate bearish trends on both weekly and monthly time frames. The stock has underperformed significantly compared to the S&P 500 across all multi-period returns, with a 1-year return of -41.33% versus the S&P 500's 16.90%...."
      },
      {
        "title": "ImmunityBio, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/immunitybio-inc-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-price-decline-3640470",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ImmunityBioInc_technicaldot_3640470.png",
        "date": "2025-10-20 15:26:33",
        "description": "ImmunityBio, Inc. has recently revised its stock evaluation amid changing market conditions. Currently priced at $2.40, the stock has experienced a significant decline over the past year, underperforming compared to the S&P 500. Technical indicators suggest a mixed outlook, reflecting ongoing challenges for the company."
      },
      {
        "title": "Is ImmunityBio, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immunitybio-inc-technically-bullish-or-bearish-3548272",
        "imagepath": "",
        "date": "2025-09-20 20:13:49",
        "description": "As of 9 September 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but is bearish on the monthly. The Bollinger Bands indicate a bullish trend weekly but are mildly bearish monthly. Moving averages are mildly bearish on the daily timeframe, while the KST and Dow Theory both reflect bearish conditions on the monthly scale but mildly bullish on the weekly. The OBV is consistently mildly bullish across both timeframes.\n\nIn terms of performance, ImmunityBio has outperformed the S&P 500 over the past week and month, returning 10.04% and 17.28% respectively, but has significantly underperformed over the longer term, with a 1-year return of -16.67% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is ImmunityBio, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-immunitybio-inc-overvalued-or-undervalued-3544360",
        "imagepath": "",
        "date": "2025-09-20 18:44:12",
        "description": "As of 12 August 2024, ImmunityBio, Inc. has moved from a grade of \"does not qualify\" to \"risky.\" The company is considered overvalued based on its current financial metrics. Key valuation ratios include a Price to Book Value of -4.70, an EV to EBIT of -11.19, and an EV to EBITDA of -11.83, all indicating significant financial distress and negative performance relative to its assets and earnings.\n\nIn comparison to peers, ImmunityBio's P/E ratio is -5.48, while TG Therapeutics, Inc. is very expensive with a P/E of 83.91, and Mirum Pharmaceuticals, Inc. also carries a risky designation with a P/E of -66.39. This highlights the challenges ImmunityBio faces in the market. Despite a recent 1-week return of 10.04% compared to the S&P 500's 1.05%, the longer-term performance shows a stark contrast, with a 5-year return of -66.43% against the S&P 500's 96.61%, reinforcing the notion that the stock is overvalued...."
      }
    ],
    "total": 12,
    "sid": "1241474",
    "stock_news_url": "https://www.marketsmojo.com/news/immunitybio-inc-1241474"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

ImmunityBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-28 15:49:53

ImmunityBio, Inc. has recently revised its evaluation amid market fluctuations, with its stock price at $2.66. The company has experienced significant volatility over the past year, with a 52-week high of $6.82 and a low of $1.83. Its performance has lagged behind the S&P 500 in both short and long-term comparisons.

Is ImmunityBio, Inc. technically bullish or bearish?

2025-10-28 11:44:58

As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on the weekly timeframe but bearish on the monthly, while the RSI is bullish weekly but shows no signal monthly. Bollinger Bands and KST indicate a bearish outlook on both weekly and monthly periods. Moving averages are bearish on the daily timeframe, and Dow Theory reflects a mildly bearish stance weekly with no trend monthly. In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -41.33% compared to the S&P 500's 16.90%, and a 5-year return of -71.21% versus 95.99% for the index....

Is ImmunityBio, Inc. technically bullish or bearish?

2025-10-27 11:56:00

As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis, while the RSI indicates bullish momentum weekly but shows no signal monthly. Bollinger Bands and KST are both mildly bearish on a weekly basis, and moving averages are bearish daily. The Dow Theory reflects a mildly bearish stance weekly with no trend monthly. Overall, the mixed signals suggest caution, and there is no available return data to compare the company's performance against the S&P 500....

Is ImmunityBio, Inc. technically bullish or bearish?

2025-10-26 11:31:07

As of 24 October 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators: the MACD is mildly bullish on a weekly basis but bearish monthly, while the RSI is bullish weekly with no signal monthly. However, moving averages are bearish daily, and the KST and Dow Theory indicate bearish trends on both weekly and monthly time frames. The stock has underperformed significantly compared to the S&P 500 across all multi-period returns, with a 1-year return of -41.33% versus the S&P 500's 16.90%....

ImmunityBio, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-20 15:26:33

ImmunityBio, Inc. has recently revised its stock evaluation amid changing market conditions. Currently priced at $2.40, the stock has experienced a significant decline over the past year, underperforming compared to the S&P 500. Technical indicators suggest a mixed outlook, reflecting ongoing challenges for the company.

Is ImmunityBio, Inc. technically bullish or bearish?

2025-09-20 20:13:49

As of 9 September 2025, the technical trend for ImmunityBio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but is bearish on the monthly. The Bollinger Bands indicate a bullish trend weekly but are mildly bearish monthly. Moving averages are mildly bearish on the daily timeframe, while the KST and Dow Theory both reflect bearish conditions on the monthly scale but mildly bullish on the weekly. The OBV is consistently mildly bullish across both timeframes. In terms of performance, ImmunityBio has outperformed the S&P 500 over the past week and month, returning 10.04% and 17.28% respectively, but has significantly underperformed over the longer term, with a 1-year return of -16.67% compared to the S&P 500's 17.14%....

Is ImmunityBio, Inc. overvalued or undervalued?

2025-09-20 18:44:12

As of 12 August 2024, ImmunityBio, Inc. has moved from a grade of "does not qualify" to "risky." The company is considered overvalued based on its current financial metrics. Key valuation ratios include a Price to Book Value of -4.70, an EV to EBIT of -11.19, and an EV to EBITDA of -11.83, all indicating significant financial distress and negative performance relative to its assets and earnings. In comparison to peers, ImmunityBio's P/E ratio is -5.48, while TG Therapeutics, Inc. is very expensive with a P/E of 83.91, and Mirum Pharmaceuticals, Inc. also carries a risky designation with a P/E of -66.39. This highlights the challenges ImmunityBio faces in the market. Despite a recent 1-week return of 10.04% compared to the S&P 500's 1.05%, the longer-term performance shows a stark contrast, with a 5-year return of -66.43% against the S&P 500's 96.61%, reinforcing the notion that the stock is overvalued....

View All News